Pharmacovigilance in rural India: challenges, opportunities and the way forward
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261974Keywords:
Pharmacovigilance, Rural India, Adverse drug reactions, Community health workers, Delay-tolerant networking, PvPI, mHealthAbstract
Pharmacovigilance (PV) plays a crucial role in safeguarding drug safety, yet its reach in rural India, home to approximately 65% of the population, remains markedly limited compared to urban centres. Drawing from our experiences in adverse drug reaction (ADR) monitoring at peripheral health centres, this article explores key barriers, including inadequate awareness, infrastructural deficits, and sociocultural hurdles, that hinder effective PV implementation. It highlights opportunities through community health workers (CHWs), low-bandwidth mobile technologies, and innovative models such as Delay-Tolerant Networking (DTN) for offline reporting. Recommendations include embedding PV within existing national programs like the National Health Mission (NHM) and Ayushman Bharat Digital Mission (ABDM), enhancing contextualised training, and pursuing policy reforms through the PV Programme of India (PvPI). By systematically addressing these gaps, India can acheive more equitable drug safety, reduce preventable ADRs, and strengthen public health in its most underserved communities. This review offers practical, field-informed insights for policymakers, practitioners, and program implementers.
References
WHO. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organisation. 2002.
Patel PB, Desai CK. Pharmacovigilance in India: past, present and future. J Pharmacol Pharmacother. 2010;1(2):114-6.
Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI): Annual Report 2023-24. Ghaziabad: IPC. 2024.
Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 2000;22(6):415-23.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of hospital admission: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-9.
Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60(17):1750-9.
Biswas M, Roy MN, Mahatab-ul-Anwar M, Husain MG, Datta S, Biswas A, et al. Adverse drug reactions in hospitalised patients: an aetiological study. J Clin Diagn Res. 2013;7(11):2521-5.
Sood A, Prajapati H, Gupta A. Pharmacovigilance analysis in a rural tertiary care hospital in North India: a retrospective study. Int J Basic Clin Pharmacol. 2016;5(7):1425-31.
Sulakhiya K, Sharma P, Shukla S. Current scenario and prospects of adverse drug reactions (ADRs) monitoring and reporting mechanisms in the rural areas of India. Curr Drug Saf. 2023;19(2):172-90.
Gupta SK, Kharya P, Kumar A. Pharmacovigilance: a need of the hour in developing countries. Indian J Pharm Pract. 2018;11(2):85-90.
Sethi MK, Ushashree P. Pharmacovigilance: challenges in India. J Pharmacovigil. 2016;4(1):194.
Toor MN, Baig MT, Shaikh S, Shahid U, Hassan SF, Syed N. Pharmacovigilance as an essential component of pharmacotherapy at tertiary hospitals in rural areas of Pakistan. Pharmacophore. 2020;11(2):71-5.
Jain P, Sharma S, Baghel S. Training and deployment of ASHAs: experiences from a rural district in India. Indian J Public Health. 2018;62(1):16-21.
National Health Systems Resource Centre (NHSRC). ASHA program: report of the 5th common review mission. New Delhi: Ministry of Health and Family Welfare. 2022.
Chandrashekar P. The rise of mHealth in India: bridging the healthcare gap. Indian J Public Health Res Dev. 2018;9(11):32-7.
Agarwal S, Labrique A, Kumar V, Guo X, Walker DG. Mobile health (mHealth) in India: challenges and opportunities. J Health Inform Dev Ctries. 2015;9(2):11-8.
Cerf VG, Burleigh S, Hooke A, Torgerson L, Scott K, Wallace K, et al. Delay-tolerant networking architecture. IETF RFC. 2007;4838.
Patil VC, Lakkundi VD. A survey on applications of delay tolerant networks. Int J Comput Appl. 2014;93(7):18-24.
Wasiullah M, Yadav P, Yadav SK, Chauhan R. Artificial intelligence in pharmacovigilance: improving drug safety. Res Rev J Comput Biol. 2025;14(1):1-16.
Aagaard L, Hallas J, Holm L, Andersen SE. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. Pharmaceut Med. 2022;36(5):295-306.
Badary OA. The potential of artificial intelligence and machine learning in pharmacovigilance: an update. GenoMed Connect. 2025;2:0010.
Rai S, Maurya S, Singh S, Kumar S, Pal G. Artificial intelligence in detection of adverse drug reaction. Int J Sci Dev Res. 2025;10(2):124-30.
Kolhe PN, Chaudhari DN, Chandanshive V. A review on blockchain-based frameworks for enhancing security and traceability in drug supply chains. Int J Sci Res Eng Dev. 2025;8(3):1-10.
Shinde S, Chaudhari A, Garad H. A review paper on a blockchain based approach for drug traceability in healthcare and supply chain. Int Res J Eng Technol. 2024;11(12):117-22.
Gaynor M. Blockchain applications in the pharmaceutical industry. Blockchain Healthc Today. 2024;7:1-5.
Phogat P. Current scenario of pharmacovigilance in India. J Drug Discov Ther. 2020;1(1):1-6.
Ministry of Health and Family Welfare, Government of India. National Health Mission: Framework for Implementation 2022-2027. New Delhi: MoHFW. 2022.
National Health Authority. Ayushman Bharat Digital Mission: operational guidelines. New Delhi: NHA. 2022.
Downloads
Published
How to Cite
Issue
Section
